AstraZeneca Builds End-to-End Cell Therapy Hub in China

AstraZeneca plans to establish a commercial cell therapy manufacturing and supply base alongside a dedicated innovation center in Shanghai, expanding its end-to-end cell therapy capabilities in China, the company announced on March 19, 2026. The initiative supports commercial-scale production of autologous cell therapies while strengthening early-stage research and clinical development infrastructure within a major biopharmaceutical hub.¹

Concurrently, the company signed a multi-party memorandum of understanding with the Shanghai Municipal Science and Technology Commission and partners, including University of Glasgow, King's College London, and HSBC to establish a cross-border life sciences collaboration framework. This expansion reflects broader industry efforts to regionalize advanced therapy manufacturing and integrate discovery, development, and supply capabilities in key global markets.

“[We] are delighted to further our collaboration and investment in Shanghai, continuously enhancing our ability to deliver breakthrough therapies to patients in China and beyond,” said Iskra Reic, executive vice president and head of International Business, AstraZeneca, in a company press relesae.¹ “As one of China’s leading biomedical hubs, Shanghai has built a robust pathway from basic research and translational development to advanced manufacturing, fostering a vibrant innovation ecosystem. Based on this, we will launch a new ‘Shanghai-UK Life Sciences Innovation Ecosystem Collaboration’ with our partners to drive joint research, commercialization, and business expansion, enabling innovations from both the UK [United Kingdom] and Shanghai to benefit patients worldwide.”

How is AstraZeneca building end-to-end cell therapy infrastructure in China?

The company will construct a commercial manufacturing and supply base in the Lingang New Area of the Shanghai Free Trade Zone to support production of autologous chimeric antigen receptor T-cell (CAR-T) therapies for China and other Asian markets.

The facility is expected to support programs including AZD0120, a dual-target CAR-T therapy directed against B cell maturation antigen and CD19. The candidate, developed using a rapid manufacturing platform, is currently undergoing clinical evaluation in multiple myeloma and autoimmune diseases.²

In parallel, the company will establish the AstraZeneca Gracell Cell Therapy Innovation Center in Shanghai Zhangjiang High-Tech Park. The center will integrate early-stage research, viral vector and plasmid development, analytical testing, clinical manufacturing, and regulatory support.

By co-locating manufacturing and R&D infrastructure, the model aims to streamline translation from discovery to commercialization, addressing key challenges associated with complex, patient-specific therapies.

What role does cross-border collaboration play in innovation ecosystems?

Alongside the infrastructure investment, the Shanghai-UK Life Sciences Innovation Ecosystem Collaboration Program is designed to connect China’s R&D capabilities with international academic and financial institutions.

The initiative will focus on joint research, clinical studies, and commercialization strategies to accelerate development timelines for innovative therapies. It also includes support for early- and growth-stage companies through financing, market access, and business development resources.

Cross-border collaboration models are increasingly used to align regional innovation strengths with global development pathways.³

Can localized manufacturing accelerate access to advanced therapies?

The establishment of a regional cell therapy manufacturing base may help address logistical and scalability challenges associated with autologous therapies, including production timelines and supply chain complexity.

China continues to expand its role in advanced therapy development, supported by a growing clinical trial ecosystem, manufacturing capacity, and regulatory evolution. AstraZeneca’s investment reflects a broader shift among multinational biopharma companies toward embedding advanced modality capabilities within high-growth markets.⁴

By integrating manufacturing, R&D, and international collaboration, the company aims to support the development and delivery of next-generation cell therapies while strengthening its position within a key global innovation hub.

References

1. AstraZeneca. AstraZeneca announces the establishment of a commercial cell therapy manufacturing and supply base and innovation center in Shanghai. Published March March 19, 2026. Accessed March 20, 2026. https://www.astrazeneca.com.cn/zh/media/press-releases/2026/03-19-01.html
2. Richard S, Gaballa M, Gregory T, et al. Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary results from the DURGA-1 phase 1b/2 study. Transplant. Cell. Ther. 2026;32(2) Supplement:S33. doi: 10.1016/j.jtct.2025.12.054
3. Wang J, Chandra K, Du C, et al. Assessing the potential of cross-border regional innovation systems: A case study of the Hong Kong–Shenzhen region. Technology in Society 2021;65:101557. doi: 10.1016/j.techsoc.2021.101557
4. Tan R, Hua H, Zhou S, et al. Current landscape of innovative drug development and regulatory support in China. Signal Transduction Targeted Ther. 2025;10:220. doi: 10.1038/s41392-025-02267-y